Literature DB >> 10347752

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system.

K M Lima1, J M Rodrigues Júnior.   

Abstract

Successful vaccine application means maximum protection with minimal number of administrations. A rational development of vaccines involves studies of the nature of the antigen as well as of the adjuvant to be used to improve the immune responses. This has provided the impetus for studies to design the degradable devices and for different approaches to antigen delivery by different routes of administration. The development of controlled release systems based on polymeric devices that permit a sustained or pulsed release of encapsulated antigens has attracted much interest. Polymeric delivery systems consist of polymers that release their content continuously in a controlled manner over a period of time. The development of a biocompatible delivery system for parenteral administration offers several advantages in terms of immunoadjuvanticity over other compounds. It was found that, in contrast to other carriers, microspheres are more stable, thus permitting administration by the oral or parenteral route. In the present study, we describe the main characteristics and potentialities of this new immunoadjuvant for oral and parenteral administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347752     DOI: 10.1590/s0100-879x1999000200005

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  12 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Dynamics of controlled release of heparin from swellable crosslinked starch microspheres.

Authors:  A K Bajpai; Smitha Bhanu
Journal:  J Mater Sci Mater Med       Date:  2007-05-05       Impact factor: 3.896

3.  Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge.

Authors:  Angela M Arenas-Gamboa; Thomas A Ficht; Melissa M Kahl-McDonagh; Allison C Rice-Ficht
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

4.  A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity.

Authors:  Saijie Zhu; Xinran Li; Dharmika S P Lansakara-P; Amit Kumar; Zhengrong Cui
Journal:  J Pharm Pharmacol       Date:  2012-10-14       Impact factor: 3.765

5.  Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis.

Authors:  V M Lima; V L Bonato; K M Lima; S A Dos Santos; R R Dos Santos; E D Gonçalves; L H Faccioli; I T Brandão; J M Rodrigues-Junior; C L Silva
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.

Authors:  A M Arenas-Gamboa; T A Ficht; M M Kahl-McDonagh; G Gomez; A C Rice-Ficht
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

7.  Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres.

Authors:  Angela M Arenas-Gamboa; Thomas A Ficht; Donald S Davis; Philip H Elzer; Alfredo Wong-Gonzalez; Allison C Rice-Ficht
Journal:  J Wildl Dis       Date:  2009-01       Impact factor: 1.535

8.  Trehalose 6,6'-dimycolate on the surface of Mycobacterium tuberculosis modulates surface marker expression for antigen presentation and costimulation in murine macrophages.

Authors:  Celestine Kan-Sutton; Chinnaswamy Jagannath; Robert L Hunter
Journal:  Microbes Infect       Date:  2008-11-01       Impact factor: 2.700

9.  Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.

Authors:  Stacie J Fairley; Shree R Singh; Abebayehu N Yilma; Alain B Waffo; Praseetha Subbarayan; Saurabh Dixit; Murtada A Taha; Chino D Cambridge; Vida A Dennis
Journal:  Int J Nanomedicine       Date:  2013-05-30

10.  Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation.

Authors:  Roberto Nicolete; Cristina Rius; Laura Piqueras; Peter J Jose; Carlos A Sorgi; Edson G Soares; Maria J Sanz; Lúcia H Faccioli
Journal:  BMC Immunol       Date:  2008-07-15       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.